Ken Getz, assistant professor at Tufts Center for the Study of Drug Development (CSDD), reports that oftentimes procedures performed in the last drug development stages are in order to find “supplementary, secondary, tertiary, and exploratory endpoints.”...
In a recent article by Outsourcing-Pharma, Harvard Medical School scientists from Beth Israel Deaconess Medical Center (BIDMC) claim to have identified genetic differences between people who respond to placebos during trials and those who do not. Only 122 of the 262...
